Table 1.
Clinical characteristics of psoriasis patients and controls.
| Psoriasis (n = 53) |
Controls (n = 99) |
p-Value | |
|---|---|---|---|
| Demographics | |||
| Age, years | 47 (15) | 47 (11) | 0.94 |
| Women, n (%) | 16 (30) | 28 (28) | 0.81 |
| Body mass index, kg/m² | 29.2 (5.5) | 29.9 (3.9) | 0.42 |
| Physical activity, hour/week | 4.6 (3.7) | 4.1 (3.4) | 0.44 |
| High-sensitive CRP, µg/mL, median (IQR) | 1.0 (0.2–3.0) | 1.1 (0.6–3.2) | 0.33 |
| Serum creatinine, µmol/L | 75 (14) | 77 (12) | 0.54 |
| Disease duration, years | 24 (13) | - | |
| PASI at initiation of infliximab treatment | 16.1 (11.5) | - | |
| PASI current | 0.8 (0.8) | - | |
| DLQI at initiation of infliximab treatment | 17.5 (6.0) | - | |
| DLQI current | 0.7 (1.3) | - | |
| Psoriasis arthritis, n (%) | 19 (36) | - | |
| Cardiovascular risk factors | |||
| Current smoking, n (%) | 19 (37) | 15 (17) | 0.005 |
| Office systolic BP, mmHg | 137 (17) | 132 (17) | 0.11 |
| Office diastolic BP, mmHg | 87 (8) | 82 (9) | 0.003 |
| Ambulatory systolic BP, mmHg | 123 (12) | 122 (12) | 0.75 |
| Ambulatory diastolic BP, mmHg | 80 (8) | 79 (7) | 0.60 |
| Hypertension, n (%) | 31 (66) | 57 (61) | 0.54 |
| Obesity, n (%) | 18 (34) | 33 (33) | 0.94 |
| Diabetes, n (%) | 3 (6) | 5 (7) | 0.87 |
| LDL cholesterol, mmol/L | 3.4 (0.9) | 3.6 (0.9) | 0.16 |
| Statin, n (%) | 6 (11) | 11 (11) | 1.00 |
| Medication | |||
| Treated hypertension, n (%) | 15 (48) | 20 (35) | 0.22 |
| Methotrexate, n (%) | 45 (85) | - | |
| Infliximab, n (%) | 53 (100) | - | |
| Duration of infliximab treatment, years | 4.9 (3.8) | - |
BP: Blood pressure; CRP: C-reactive protein; DLQI: Dermatology life quality index; IQR: Interquartile range; LDL: Low density lipoprotein; PASI: Psoriasis area and severity index.